Context Therapeutics (CNTX) Institutional Ownership $2.27 +0.09 (+4.13%) (As of 11/1/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Context Therapeutics (NASDAQ:CNTX)CurrentInstitutional OwnershipPercentage14.03%Number ofInstitutional Buyers(last 12 months)8TotalInstitutional Inflows(last 12 months)$39.97MNumber ofInstitutional Sellers(last 12 months)0 Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CNTX Institutional Buying and Selling by Quarter Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Context Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/20/2024Nantahala Capital Management LLC1,935,484$3.88M0.2%N/A2.581% 8/16/2024Driehaus Capital Management LLC2,258,065$4.53M0.0%N/A3.011% 8/15/2024Blue Owl Capital Holdings LP5,161,290$10.35M2.9%N/A6.882% 8/15/2024Affinity Asset Advisors LLC1,619,140$3.25M0.4%+392.4%2.159% 8/14/2024Great Point Partners LLC7,419,355$14.88M2.8%N/A9.893% 8/14/2024Ally Bridge Group NY LLC1,886,232$3.78M2.3%+159.8%2.515% 8/9/2024Renaissance Technologies LLC65,200$131K0.0%+63.4%0.087% 5/29/2024Opaleye Management Inc.1,108,357$1.53M0.3%+13.7%1.478% 2/15/2024Opaleye Management Inc.975,000$1.10M0.3%N/A6.107% 11/15/2023Affinity Asset Advisors LLC328,817$497K0.1%+22.9%2.059% 8/21/2023Affinity Asset Advisors LLC267,574$428K0.1%N/A1.675% 7/21/2023 Clear Harbor Asset Management LLC36,000$58K0.0%N/A0.225% 2/16/2023AIGH Capital Management LLC1,143,745$745K0.2%-11.5%7.162% 2/14/2023swisspartners Ltd.180,000$119K0.2%+111.8%1.127% 11/14/2022Worth Venture Partners LLC322,628$358K0.2%+8.4%2.021% 11/1/2022swisspartners Ltd.85,000$94K0.1%+101.3%0.532% 8/13/2022Virtu Financial LLC46,445$98K0.0%N/A0.291% 8/12/2022Affinity Asset Advisors LLC883,654$1.87M0.8%+13.6%5.535% 5/4/2022swisspartners Ltd.14,315$4.98M3.5%-66.1%0.090% 2/14/2022Altium Capital Management LP493,531$1.31M0.4%N/A4.501% 2/11/2022QCM Cayman Ltd.14,041$37K0.2%N/A0.128% 2/10/2022AIGH Capital Management LLC762,721$2.03M0.6%N/A6.955% 2/9/2022swisspartners Ltd.42,235$114K0.1%N/A0.385% (Data available from 1/1/2016 forward) CNTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CNTX shares? During the previous two years, 12 institutional investors and hedge funds held shares of Context Therapeutics. The most heavily invested institutionals were Great Point Partners LLC ($14.88M), Blue Owl Capital Holdings LP ($10.35M), Driehaus Capital Management LLC ($4.53M), Nantahala Capital Management LLC ($3.88M), Ally Bridge Group NY LLC ($3.78M), Affinity Asset Advisors LLC ($3.25M), and Opaleye Management Inc. ($1.53M).Learn more on CNTX's institutional investors. What percentage of Context Therapeutics stock is owned by institutional investors? 14.03% of Context Therapeutics stock is owned by institutional investors. Learn more on CNTX's institutional investor holdings. Which institutional investors have been buying Context Therapeutics stock? Of the 11 institutional investors that purchased Context Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Great Point Partners LLC ($7.42M), Blue Owl Capital Holdings LP ($5.16M), Driehaus Capital Management LLC ($2.26M), Nantahala Capital Management LLC ($1.94M), Affinity Asset Advisors LLC ($1.62M), Ally Bridge Group NY LLC ($1.16M), and Opaleye Management Inc. ($1.11M). How much institutional buying is happening at Context Therapeutics? Institutional investors have bought a total of 20,843,288 shares in the last 24 months. This purchase volume represents approximately $40.55M in transactions. Which Context Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Context Therapeutics stock in the last 24 months: AIGH Capital Management LLC ($148.03K). How much institutional selling is happening at Context Therapeutics? Institutional investors have sold a total of 148,026 shares in the last 24 months. This volume of shares sold represents approximately $96.47K in transactions. Related Companies UNCY Major Shareholders ABVX Major Shareholders ATXS Major Shareholders YMAB Major Shareholders STOK Major Shareholders TRDA Major Shareholders TNGX Major Shareholders SLRN Major Shareholders HUMA Major Shareholders EXAI Major Shareholders This page (NASDAQ:CNTX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
